SPEARHEAD launches to address the silent pandemic of antimicrobial resistance (AMR)
Today, a consortium of 8 public and 4 private Swiss institutions has joined forces to address the silent pandemic of antimicrobial resistance (AMR) by launching the ‘Swiss Pandemic & AMR – Health Economy Awareness Detect’ (SPEARHEAD) partnership.
AMR is the ability of microorganisms (like bacteria, viruses, and some parasites) to prevent antimicrobials (such as antibiotics, antivirals and antimalarials) from working against them. As a result, many treatments are becoming ineffective against infections that were previously easily treatable.
SPEARHEAD will leverage lessons learnt to address the steadily worsening, silent pandemic of AMR, with potentially 10M deaths per year globally by 2050 (4 x the 2020 COVID-19 death toll) and the related economic impact on society.
SPEARHEAD builds on the partners’ existing expertise in COVID-19 and AMR to rapidly deploy digital pandemic responses to address AMR. The project has five main goals:
- real-time data flow to and from decision-makers
- better use of big data for risk stratification
- timely diagnostics that can leapfrog a centralized laboratory infrastructure
- better and broader citizen and community engagement as well as
- early attention to the financial implications of the proposed innovations.
These goals will be used to mitigate the expected economic and societal impacts of AMR.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.